Compare INLX & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | PLUR |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 25.5M |
| IPO Year | 2013 | 2001 |
| Metric | INLX | PLUR |
|---|---|---|
| Price | $5.66 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 857.0 | ★ 16.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | $11,336.00 | ★ $1,336,000.00 |
| Revenue This Year | $16.86 | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $5.21 | $1.45 |
| 52 Week High | $12.48 | $5.68 |
| Indicator | INLX | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 49.09 |
| Support Level | $5.37 | $1.56 |
| Resistance Level | $7.87 | $1.86 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 60.96 | 62.70 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.